Page last updated: 2024-11-05

deoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Deoxyuridine is a nucleoside composed of deoxyribose and uracil. It is a naturally occurring compound found in small amounts in DNA. Deoxyuridine can be synthesized through various methods, including enzymatic reactions and chemical synthesis. It has been studied for its potential therapeutic effects in cancer treatment, specifically in inhibiting DNA synthesis. Deoxyuridine can act as a substrate for thymidylate synthase, an enzyme crucial for DNA replication. By inhibiting this enzyme, deoxyuridine can potentially block the synthesis of thymidine, a key component of DNA. This inhibition of DNA replication can lead to cell death and potentially inhibit tumor growth. Deoxyuridine has also been investigated for its potential role in radiation therapy, where it can enhance the effectiveness of radiation treatment. It is believed that deoxyuridine can increase the sensitivity of cancer cells to radiation by interfering with DNA repair mechanisms. Despite its potential therapeutic applications, deoxyuridine's clinical use is limited due to its lack of specificity and potential side effects. Researchers continue to investigate its therapeutic potential and explore ways to improve its selectivity and efficacy.'

Cross-References

ID SourceID
PubMed CID13712
CHEMBL ID353955
CHEBI ID16450
SCHEMBL ID28844
MeSH IDM0006020

Synonyms (65)

Synonym
smr000112296
MLS001066344
w78i7ay22c ,
unii-w78i7ay22c
AKOS015833069
1-(2-deoxy-beta-d-erythro-pentofuranosyl)uracil
CHEBI:16450 ,
nsc-23615
uracil deoxyriboside
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
1-((2r,4s,5r)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1-h-pyrimidine-2,4-dione
1-(2-deoxy-beta-d-ribofuranosyl)uracil
C00526
2'-deoxyuridine ,
951-78-0
DEOXYURIDINE ,
DUR ,
2'-deoxyuridine, >=98.5%
DB02256
NCGC00142492-01
nsc 23615
einecs 213-455-7
brn 0024433
uridinie, 2'-deoxy-
E73B1553-A13A-4989-B045-A589A8F2B9DC
D0060
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
zinc00155696
BMSE000320
CHEMBL353955
1-[(4s,2r,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2, 4-dione
1-(2-deoxy-ss-d-ribofuranosyl)uracil
HMS2267D16
1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
AKOS015896792
deoxyuridine [mi]
1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)uracil
S5505
1-(2-deoxy-d-erythro-pentofuranosyl)uracil
SCHEMBL28844
2YB0
J-700048
MXHRCPNRJAMMIM-SHYZEUOFSA-N
desoxyuridine
uracil desoxyuridine
PS-7750
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
mfcd00006527
2'-du
CCG-247504
1-(2-deoxy-beta-delta-erythro-pentofuranosyl)-2,4(1h,3h)-pyrimidinedione
1-(2-deoxy-beta-delta-ribofuranosyl)-2,4(1h,3h)-pyrimidinedione
1-(2-deoxy-delta-erythro-pentofuranosyl)uracil
1-(2-deoxy-beta-d-erythro-pentofuranosyl)-2,4(1h,3h)-pyrimidinedione
1-(2-deoxy-beta-d-ribofuranosyl)-2,4(1h,3h)-pyrimidinedione
HY-D0186
1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydro-furan-2-yl)pyrimidine-2,4(1h,3h)-dione
CS-W019820
Q419140
AMY6955
2'-deoxyuridine-1'-d
O10766
DTXSID30883621
EN300-7374520
BP-58660

Research Excerpts

Overview

Deoxyuridine (dUrd) is a naturally occurring modified form of Urd. It is not one of the canonical DNA nucleosides.

ExcerptReferenceRelevance
"Deoxyuridine (dU) excision is an approach for generating 3' ssDNA overhangs in gene assembly and molecular cloning procedures."( Efficient Linear dsDNA Tagging Using Deoxyuridine Excision*.
Strobel, EJ, 2021
)
1.62
"2'-Deoxyuridine (dUrd) is a naturally occurring modified form of Urd, but is not one of the canonical DNA nucleosides."( Effects of sodium cationization versus protonation on the conformations and N-glycosidic bond stabilities of sodium cationized Urd and dUrd: solution conformation of [Urd+Na]
Berden, G; Cunningham, NA; Gao, J; Munshi, MU; Oomens, J; Rodgers, MT; Roy, HA; Strobehn, SF; Zhu, Y, 2017
)
0.97

Effects

ExcerptReferenceRelevance
"Iododeoxyuridine (IUdR) has a very short in vivo half-life and consequently achieves low target-tissue concentrations with concomitant lower efficacy than would be predicted from in vitro studies. "( Preparation and preliminary evaluation of novel beta-cyclodextrin/IUDR prodrug formulations.
Diakur, J; Singh, S; Wiebe, LI; Yang, XH, 2008
)
0.9
"Iododeoxyuridine (IUdR) has a very short in vivo half-life and consequently achieves low target-tissue concentrations with concomitant lower efficacy than would be predicted from in vitro studies. "( Preparation and preliminary evaluation of novel beta-cyclodextrin/IUDR prodrug formulations.
Diakur, J; Singh, S; Wiebe, LI; Yang, XH, 2008
)
0.9

Actions

ExcerptReferenceRelevance
"Deoxyuridine does not increase the normal dNTP pools but gives rise to a small dUTP and a large dUMP pool, both turning over rapidly."( Mitochondrial deoxynucleotide pools in quiescent fibroblasts: a possible model for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Bianchi, V; Crocco, L; Fabris, S; Ferraro, P; Pontarin, G; Reichard, P, 2005
)
1.05

Toxicity

ExcerptReferenceRelevance
"N2O is a relatively safe general anaesthetic under normal medical and dental anaesthetic use."( Myelotoxic, neurotoxic and reproductive adverse effects of nitrous oxide.
Louis-Ferdinand, RT, 1994
)
0.29
" While the mechanism(s) of this toxicity remains elusive, alternative strategies are being developed to reduce these toxic effects, including combination therapy with nonmyelotoxic antihuman immunodeficiency virus drugs and/or administration of protective or rescue agents, including cytokines and growth factors."( Protection and rescue from 2',3'-dideoxypyrimidine nucleoside analog toxicity by hemin in human bone marrow progenitor cells.
Fowler, DA; Sommadossi, JP; Xie, MY, 1996
)
0.29
" RTX induces proliferating tissue toxicities that are largely confined to the intestine, with diarrhea being a severe side effect in a small but significant minority of patients."( Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
Aherne, GW; Benstead, J; Clarke, SJ; Farrugia, DC; Jackman, AL; Pritchard, DM, 2000
)
0.31
" There are no toxic effects of 5-fodUrd on cells defective in thymidine kinase or thymidylate synthetase, suggesting that the toxicity may be caused by 5-fodUrd phosphorylation and subsequent inhibition of thymidylate synthetase."( 5-Formyluracil and its nucleoside derivatives confer toxicity and mutagenicity to mammalian cells by interfering with normal RNA and DNA metabolism.
Bjelland, S; Klungland, A; Matsuda, A; Paulsen, R; Rolseth, V; Seeberg, E; Ueno, Y; Wiik, P; Yamada, Y, 2001
)
0.31
" Our results demonstrate that elevated concentrations (similar to manufacturers suggested concentration; >5-10 μM) of EdU treatment were toxic to the cell cultures, particularly in cells with a defect in homologous recombination repair."( Evaluating the Genotoxic and Cytotoxic Effects of Thymidine Analogs, 5-Ethynyl-2'-Deoxyuridine and 5-Bromo-2'-Deoxyurdine to Mammalian Cells.
Allum, AJ; Froning, CE; Haskins, AH; Haskins, JS; Kato, TA; Maeda, J; Su, C; Walsh, KD, 2020
)
0.78
"The recent development of human cerebral organoids provides an invaluable in vitro model of human brain development to assess the toxicity of natural or man-made toxic substances."( Evaluation of Neurotoxicity With Human Pluripotent Stem Cell-Derived Cerebral Organoids.
Lalonde, J; LaMarre, J; Parmentier, T, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic behaviour of the virostatic drug 5-ethyl-2'-deoxyuridine (EtUdR, Aedurid) and its metabolite 5-ethyluracil was determined after intravenous and oral application in a nonindividual study using inbred rats."( [Pharmacokinetics of 5-ethyl-2'-desoxyuridine in the rat].
Hempel, B; Kaul, R, 1985
)
0.51
" EDU was eliminated from blood with a half-life of 35."( Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
Cheraghali, AM; Knaus, EE; Kumar, R; Wiebe, LI, 1995
)
0.54
" The blood level curves were analyzed by appropriate pharmacokinetic models."( [Pharmacokinetic studies of 14C-labeled epervudine in rats].
Dereszlay, I; Vereczkey, L, 1993
)
0.29
" administration can be characterized by a two-compartment open pharmacokinetic model."( [Pharmacokinetic studies of epervudine in rats using HPLC].
Csárdi, A; Dereszlay, I; Mészáros, S; Pátfalusi, M; Vereczkey, L, 1993
)
0.29
" Chromatograms and pharmacodynamic data from a Phase 1 Clinical Trial of a new antifolate drug, ZD9331 are included to illustrate the utility of the method."( Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.
Jackman, AL; Lynn, S; Mitchell, F, 2000
)
0.53
" This study assessed the tolerance to Ro 09-4889 treatment, and related pharmacokinetic and pharmacodynamic data such as inhibition of DPD activity in peripheral blood mononuclear cells (PBMCs) and plasma uracil levels."( Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Banken, L; Bellibas, SE; Brivet, B; Bush, ED; Chamorey, E; Kircher, C; Milano, G; Nave, S; Patel, I; Renée, N, 2004
)
0.32
" In conclusion, the LC-MS method developed is simple, highly selective and sensitive and permits pharmacodynamic studies of TS inhibitors in several species."( Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Clarke, SJ; Li, KM; Rivory, LP, 2005
)
0.61
"The purpose of this study was to investigate the utility of plasma pharmacokinetic and pharmacodynamic measures including plasma deoxynucleosides, homocysteine and methylmalonic acid concentrations in understanding the time course and extent of the inhibition of thymidylate synthase (TS) by pemetrexed in the context of a phase I/II combination study with vinorelbine."( Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
Clarke, SJ; Li, KM; Rivory, LP, 2007
)
0.34
" Pharmacokinetic parameters were estimated using non-compartmental analysis."( Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Beijnen, JH; Derissen, EJ; Huitema, AD; Jacobs, BA; Rosing, H; Schellens, JH, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"The antiviral activity and cytotoxicity of (E)-5-(2-bromovinyl)-2'-deoxycytidine (BrVdCyd) against herpes simplex virus type 1 (HSV-1), singly and in combination with deaminase inhibitors was determined using rabbit kidney (RK-13), HEP-2, BHK-21 and VERO cells."( Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2'-deoxycytidine in combination with deaminase inhibitors.
Aduma, PJ; De Clercq, E; Gupta, SV, 1990
)
0.28
"Patients with advanced or metastatic cancer were treated with escalating doses of LY2334737 monotherapy or in combination with continuous daily administration of 100 mg erlotinib."( Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO, 2011
)
0.37
"This Phase 1 study aimed to determine the recommended Phase 2 dose of LY2334737, an oral gemcitabine prodrug, when combined with standard dose docetaxel treatment in patients with advanced solid tumors."( Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER, 2014
)
0.4
" PK data were consistent with the first-in-man study of LY2334737 and did not reveal any drug-drug interaction between LY2334737 and docetaxel."( Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER, 2014
)
0.4
"Background This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of gemcitabine, in combination with capecitabine, an oral pro-drug of 5-fluorouracil, in patients with advanced solid tumors."( Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
Adjei, AA; Bendell, J; Benhadji, KA; Callies, S; Dy, GK; Fetterly, G; Infante, JR; Ma, WW, 2015
)
0.42
" The haematological toxicity score in combination with the dUr levels at C1-24 h and C4-24 h predicted early clinical response (p = 0."( Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021
)
1.08

Bioavailability

The pharmacokinetics and oral (po) bioavailability of 5-ethyl-2'-deoxyuridine (EDU) and its novel 5,6-dihydro prodrugs (+)-trans-(5R,6R) were determined in male Balb/C mice.

ExcerptReferenceRelevance
" EDU showed a 49% bioavailability in mice after a 100 mg/kg po dose."( Bioavailability and pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine.
Cheraghali, AM; Knaus, EE; Wiebe, LI, 1994
)
0.53
" The ratio of areas under serum level curves following oral and intravenous administration proves a good bioavailability (90%) of Epervudine."( [Pharmacokinetic studies of epervudine in rats using HPLC].
Csárdi, A; Dereszlay, I; Mészáros, S; Pátfalusi, M; Vereczkey, L, 1993
)
0.29
" As oral bioavailability is high (70-100%), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and dose escalated from 80 to 572 mg m(-2) day(-1) in 23 patients."( A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Boddy, A; Bowman, A; Byrne, B; Clendeninn, NJ; Jodrell, DI; Johnston, A; Rafi, I; Rye, R; Taylor, GA, 1999
)
0.3
" Forty to 50% of the administered dose was recovered in the urine, indicating a good bioavailability and resulting significant systemic exposure to the drug, which may enable chronic oral treatment."( Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
Fukuoka, M; Kudoh, S; Masuda, N; Matsui, K; Myobudani, H; Nakagawa, K; Negoro, S; Nemoto, S; Nihira, S; Nogami, T; Ogawa, K; Okuda, T; Takeda, K; Takifuji, N; Yamada, M; Yamamoto, N, 2000
)
0.31
" Through structure optimization, the o-methylbenzyl analog (1t) was identified as an orally bioavailable and liver-targeted lead compound."( Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J, 2016
)
0.67
" This work led us to propose a model in which the human DNA helicase RECQ1 acts as a governor of the single-stranded DNA binding protein RPA and regulates its bioavailability for DNA synthesis."( Single-Molecule DNA Fiber Analyses to Characterize Replication Fork Dynamics in Living Cells.
Banerjee, T; Brosh, RM; Datta, A; Dhar, S, 2019
)
0.51
" Flow cytometry detected the EdU incorporation, representing the bioavailability of EdU."( In Vivo Labeling and Tracking of Proliferating Corneal Endothelial Cells by 5-Ethynyl-2'-Deoxyuridine in Rabbits.
Correll, MH; Crouzet, E; de la Cour, MD; Gain, P; He, Z; Heegaard, S; Kiilgaard, JF; Thuret, G; Udsen, MS, 2021
)
0.84
" To date, using a variety of methods, only the bioavailability time of tritiated thymidine and 5-bromo-2'-deoxyuridine (BrdU) have been evaluated."( The bioavailability time of commonly used thymidine analogues after intraperitoneal delivery in mice: labeling kinetics in vivo and clearance from blood serum.
Belousov, VV; Enikolopov, GN; Maltsev, DI; Mellanson, KA; Podgorny, OV, 2022
)
0.93

Dosage Studied

Pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine (EDU) were determined following intravenous (iv) and oral (po) dosing in male Balb-C mice and male Sprague-Dawley rats.

ExcerptRelevanceReference
" Intramuscular injection of 5-ethyl-dUrd at a concentration as high as 2,000 mg/kg per day for 10 days was well tolerated by uninfected animals, and HSV-2-infected mice treated at this dosage had a 100% survival rate."( Effect of treatment with 5-ethyl-2'-deoxyuridine on herpes simplex virus encephalitis in normal and immunosuppressed mice.
Davis, WB; Oakes, JE; Taylor, JA, 1978
)
0.53
" Similar dose-response curves were found for the two precursors, with a peak at 15 microgram/ml of PHA."( The use of [125I]deoxyuridine for semi-microevaluation of human lymphocyte response to phytohemagglutinin in vitro.
Frati, L; Menconi, E; Neri, M; Sorci, V, 1978
)
0.6
" At each dosage level, semilogarithmic plots of concentration vs."( Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver.
Joly, JM; Williams, WM,
)
0.39
" After 13-week exposures the animals' splenic lymphocytes showed increased [3H]-TdR uptake following high N2O dosing in both the mitogen-induced blastogenesis and MLC assays."( Short term toxicity of nitrous oxide on the immune, hemopoietic, and endocrine systems in CD-1 mice.
Drown, DB; Healy, CE; Sharma, RP, 1990
)
0.28
" After a 4 hr incubation period, [5-3H]-2'-deoxyuridine was added to cultures of human colon carcinoma cells (HCT-8) in vitro and four dose-response curves were generated for each drug by sampling the culture medium for tritiated H2O formation 4, 24, 48 and 72 hr later."( Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay.
Aschele, C; Nicolin, A; Romanini, A; Rosso, R; Sobrero, A,
)
0.62
" At an optimum dosage level of 40 mg/kg, 7 and 8 produced 90% and 60% "cures" (greater than 60-day survivors), respectively."( Antineoplastic activity of 3'-(chloroethyl)nitrosourea analogues of 2'-deoxyuridine and 2'-deoxy-5-fluorouridine.
Brubaker, WF; Lin, TS; Park, S; Prusoff, WH; Wang, ZH, 1986
)
0.5
" Against HSV-1 encephalitis, CEDU exerted a significant protective effect at a dosage of 50 mg/kg per day when administered intraperitoneally."( Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.
De Clercq, E; Rosenwirth, B, 1985
)
0.48
" For comparisons of different treatment modalities any single assay seems adequate provided a dose-response relationship can be demonstrated."( Is any single in situ assay of tumour response adequate?
Denekamp, J, 1980
)
0.26
"Pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine (EDU) were determined following intravenous (iv) and oral (po) dosing in male Balb-C mice and iv dosing in male Sprague-Dawley rats."( Bioavailability and pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine.
Cheraghali, AM; Knaus, EE; Wiebe, LI, 1994
)
0.79
" The radioactivity remaining in blood after dosing with these 5-bromo-6-alkoxy-5,6-dihydro-AZTs was up to 20-fold higher than after injection of [2-(14)C]-AZT at longer time intervals after injection."( In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine.
Baker, GB; Cheraghali, M; Knaus, EE; Kumar, R; Morin, KW; Todd, KG; Wang, L; Wiebe, LI, 1996
)
0.29
" Nolatrexed plasma concentrations 1 h after dosing were 6-16 microg ml(-1), and trough 3-8 microg ml(-1), at 572 mg m(-2) day(-1)."( A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Boddy, A; Bowman, A; Byrne, B; Clendeninn, NJ; Jodrell, DI; Johnston, A; Rafi, I; Rye, R; Taylor, GA, 1999
)
0.3
" Also, food effect was assessed separately in a group dosed with 20 mg of the compound."( Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Banken, L; Bellibas, SE; Brivet, B; Bush, ED; Chamorey, E; Kircher, C; Milano, G; Nave, S; Patel, I; Renée, N, 2004
)
0.32
"Labeling of ADSC was examined for the dosage effect of EdU and stability of label by Alexa-594 staining followed by fluorescence microscopy."( Labeling and tracking of mesenchymal stromal cells with EdU.
Banie, L; Huang, YC; Lin, CS; Lin, G; Lue, TF; Shindel, AW; Wang, G, 2009
)
0.35
" Here, we show that two commonly used post-operative buprenorphine dosing regimes significantly inhibit the proliferation of doublecortin-positive neuroblasts but not other hippocampal stem and progenitor cell populations in adult mice."( The opiate analgesic buprenorphine decreases proliferation of adult hippocampal neuroblasts and increases survival of their progeny.
Bennett, SA; Desroches, R; Pettit, AS, 2012
)
0.38
"At the recommended dosage of 10(-8) mol/L, EdU is non-toxic to ADSCs."( Effects of EdU labeling on mesenchymal stem cells.
Albersen, M; Lin, CS; Lin, G; Lue, TF; Ning, H, 2013
)
0.39
" Oral dosing of mice results in absorption of intact prodrug with slow systemic hydrolysis yielding higher plasma levels of LY2334737 than gemcitabine and prolonged gemcitabine exposure."( Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER, 2013
)
0.39
" The toxicities observed at the 40 mg dose may require the development of alternative dosing schedules."( Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Benhadji, KA; Makiuchi, T; Nokihara, H; Sekiguchi, R; Slapak, CA; Tamura, T; Uenaka, K; Yamada, Y; Yamamoto, N, 2013
)
0.39
" This occurs, not only in vitro in cell lines, but also in vivo upon oral dosing to dogs."( Discovery of β-d-2'-deoxy-2'-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication.
Almeida, M; Ayesa, S; Eneroth, A; Kalayanov, G; Lindqvist, A; Pinho, P; Rosenquist, Å; Sund, C; Targett-Adams, P; Tejbrant, J; Wähling, H; Westerlind, H, 2017
)
0.46
" Isobologram models, zero interaction potency dose-response surface plots and matrices were generated to evaluate the combination synergism of the two drugs."( Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles.
Gupta, U; Hira, SK; Manna, PP; Paladhi, A; Singh, R; Singh, RA; Srivastava, DN; Srivastava, P, 2020
)
0.76
" Although 1 had a favorable in vitro activity profile in HCV replicons, oral dosing in dog resulted in low levels of the active 5'-triphosphate (TP) in liver."( Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Bow, DAJ; Carr, RA; Chen, HJ; Chris Krueger, A; DeGoey, DA; Dekhtyar, T; Heyman, HR; Irvin, M; Krishnan, P; Li, T; Peterkin, V; Randolph, JT; Stolarik, D; Van Handel, C; Wagner, R, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (17)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Salvage Pathways of Pyrimidine Deoxyribonucleotides514
Pyrimidine Deoxyribonucleosides Degradation410
Pyrimidine Deoxyribonucleosides Salvage815
superpathway of pyrimidine deoxyribonucleoside salvage619
pyrimidine deoxyribonucleosides salvage615
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Deoxy-uridine + Orthophosphate = 2-Deoxy-D-ribose 1-phosphate + Uracil ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Biomarkers for pyrimidine metabolism disorders1432
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
pyrimidine deoxyribonucleosides degradation714
superpathway of pyrimidine deoxyribonucleosides degradation738
superpathway of pyrimidine deoxyribonucleoside salvage2222
pyrimidine deoxyribonucleosides salvage1517
salvage pathways of pyrimidine deoxyribonucleotides432
superpathway of ribose and deoxyribose phosphate degradation024
(deoxy)ribose phosphate degradation018
Pyrimidine metabolism038
Pyrimidine metabolism and related diseases1844

Protein Targets (7)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, DutpaseLeishmania majorKd140.0000140.0000140.0000140.0000AID977611
Chain A, DutpaseLeishmania majorKd140.0000140.0000140.0000140.0000AID977611
Chain B, DutpaseLeishmania majorKd140.0000140.0000140.0000140.0000AID977611
Chain A, DutpaseLeishmania majorKd140.0000140.0000140.0000140.0000AID977611
Chain B, DutpaseLeishmania majorKd140.0000140.0000140.0000140.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)ID50400.00002.00002.00002.0000AID210695
Thymidine phosphorylaseHomo sapiens (human)Km559.00000.16000.16000.1600AID211066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID56582Inhibitory activity against deoxycytidine kinase from L1210 cells1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis and biological activity of various 3'-azido and 3'-amino analogues of 5-substituted pyrimidine deoxyribonucleosides.
AID139989Competition studies were performed to study effect on zero-trans influx of [6-3H]thymidine into mouse erythrocytes and inhibitory constant was determined1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and tumor uptake of 5-halo-1-(2'-fluoro-2'-deoxy-beta-D-ribofuranosyl)[2-14C]uracils.
AID139990Inhibition constant assumed to reflect the affinity for the transport site in mouse erythrocytes1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID381855Activity of Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID527281Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID210695Compound was tested for inhibit phosphorylation of [3H]-D-T catalyzed by HSV 1 thymidine kinase1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth.
AID232840Ratio of Vmax to that of dThd (Vmax = 0.14)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID211066Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID142331Thymidine Influx Inhibition constant for the compound in fresh Murine Erythrocytes1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine.
AID210869Inhibitory activity against thymidine kinase (TK) from L1210 cells1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis and biological activity of various 3'-azido and 3'-amino analogues of 5-substituted pyrimidine deoxyribonucleosides.
AID210894The compound was tested for relative phosphorylation by purified human Thymidine Kinase (TK2)1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2.
AID210893The compound was tested for relative phosphorylation by recombinant human Thymidine Kinase (TK1)1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2.
AID210890Ability to inhibit rat cytoplasmic Thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID1136939Competitive inhibition of Escherichia coli B thymidine kinase using [2-14C]-thymidine as substrate assessed as formation of [14C]-TMP after 10 mins by Lineweaver-Burk double reciprocal plot analysis1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Design of species- or isozyme-specific enzyme inhibitors. 2. Differences between a bacterial and a mammalian thymidine kinase in the effect of thymidine substituents on affinity for the thymidine site.
AID1124530Inhibition of thymidine kinase in BHK21 (C13) cells using thymidine as substrate assessed as formation of TMP at 0.1 mM1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase.
AID1124531Inhibition of thymidine kinase in BHK21 (C13) cells using thymidine as substrate assessed as formation of TMP at 0.2 mM1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase.
AID381854Activity of Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 2 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID527285Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID144640Inhibition constant was determined for the facilitated transport of [3N]-thymidine by murine erythrocyte NBMPR-sensitive nucleoside transporter.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID333392Inhibition of DNA polymerase beta lyase activity2004Journal of natural products, Oct, Volume: 67, Issue:10
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta.
AID333394Cytotoxicity against human A2780 cells2004Journal of natural products, Oct, Volume: 67, Issue:10
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta.
AID333393Inhibition of GST-fused human recombinant Cdc25B2 (275-539) catalytic domain2004Journal of natural products, Oct, Volume: 67, Issue:10
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta.
AID527283Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID1135814Dissociation constant, pKa of the compound1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID216185Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds.
AID1135815Competitive inhibition of HSV-1 pyrimidine deoxythymidine kinase using 2-[14C]deoxythymidine as substrate1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1593592Inhibition of recombinant Cryptosporidium hominis TS-DHFR expressed in Escherichia coli PA414 assessed as reduction in DHFR steady state activity at 500 uM using [3',5',7,9-3H]-H2folate as substrate preincubated for 10 mins before NADPH addition for 5 min2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
Novel allosteric covalent inhibitors of bifunctional Cryptosporidium hominis TS-DHFR from parasitic protozoa identified by virtual screening.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID139991Inhibition constant for influx competition with [6-3H]thymidine in mouse erythrocytes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and tumor uptake of 5-82Br- and 5-131I-labeled 5-halo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracils.
AID1135813Antimicrobial activity against Streptococcus faecium after 15 to 17 hrs by turbidity assay1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID126601Ability to inhibit rat mitochondrial thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID210718Compound was tested for inhibit phosphorylation of [3H]-D-T catalyzed by human thymidine kinase; Inactive at 1 uM concentration1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth.
AID248676Inhibitory concentration against HeLa cell proliferation after 72 hours of incubation; NA means not active2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
A new synthetic analogue of thymidine, 7-(3-bromo-phenoxy)-thymidine, inhibits the proliferation of tumor cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011The Journal of biological chemistry, May-06, Volume: 286, Issue:18
The crystal structure of the Leishmania major deoxyuridine triphosphate nucleotidohydrolase in complex with nucleotide analogues, dUMP, and deoxyuridine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,159)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901115 (51.64)18.7374
1990's271 (12.55)18.2507
2000's284 (13.15)29.6817
2010's396 (18.34)24.3611
2020's93 (4.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.65 (24.57)
Research Supply Index7.73 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index100.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (0.98%)5.53%
Reviews64 (2.84%)6.00%
Case Studies21 (0.93%)4.05%
Observational0 (0.00%)0.25%
Other2,149 (95.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of Induction Systemic mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone Given Concurrently With Systemic mFOLFIRI as a First-Line Therapy in Patients With Unresectable Liver-Dominant Intrahepatic Cholangio [NCT04251715]Phase 230 participants (Anticipated)Interventional2021-04-28Recruiting
A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial [NCT05863195]Phase 3408 participants (Anticipated)Interventional2023-12-19Not yet recruiting
A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors [NCT00769288]Phase 112 participants (Actual)Interventional2009-07-31Completed
A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers [NCT01749397]Phase 129 participants (Actual)Interventional2012-12-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]